<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35434024</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">2305-5839</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of translational medicine</Title>
          <ISOAbbreviation>Ann Transl Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-Ro52-positive antisynthetase syndrome (ASS): a case report and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>383</StartPage>
          <MedlinePgn>383</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">383</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.21037/atm-22-787</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">This study aimed to diagnose and treat a patient with anti-Ro52-positive antisynthetase syndrome (ASS), investigate the association between anti-Ro52 antibodies and ASS, and determine its clinical significance. The objective of this clinical report is to highlight this unusual syndrome to avoid incorrect diagnosis.</AbstractText>
          <AbstractText Label="CASE DESCRIPTION" NlmCategory="UNASSIGNED">A middle-aged woman presenting with obvious lung symptoms was admitted to our hospital. A physical examination revealed swollen joints in both hands, mechanic's hands, and normal muscle strength and muscle tone in all 4 extremities. A myositis-specific antibody panel, lung computed tomographic (CT) imaging, electromyography, and muscle biopsy were performed as auxiliary examinations, and appropriate treatment was administered after the confirmed diagnosis. The myositis-specific antibody panel yielded strongly positive results for anti-Jo-1 and anti-Ro52 antibodies, lung CT imaging revealed interstitial lung disease, electromyography revealed myogenic damage, and muscle magnetic resonance imaging revealed multiple inflammatory exudates. A definitive diagnosis of ASS was made, and glucocorticoid and immunosuppressant therapy were administered. After treatment, the patient's symptoms were alleviated, creatine kinase activity was reduced, and signs of disease activity and secondary tumors were not observed on a subsequent follow-up evaluation.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Anti-Ro52 antibodies, being myositis-associated antibodies, can lead to an atypical clinical presentation in ASS patients and are potentially associated with a poor prognosis. Therefore, thorough follow-up evaluation is required for such cases.</AbstractText>
          <CopyrightInformation>2022 Annals of Translational Medicine. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yuqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>General Medicine, International Department of China-Japan Friendship Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>General Medicine, International Department of China-Japan Friendship Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Mande</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>General Medicine, International Department of China-Japan Friendship Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Qifan</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>General Medicine, International Department of China-Japan Friendship Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Transl Med</MedlineTA>
        <NlmUniqueID>101617978</NlmUniqueID>
        <ISSNLinking>2305-5839</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-Ro52 antibody</Keyword>
        <Keyword MajorTopicYN="N">antisynthetase syndrome (ASS)</Keyword>
        <Keyword MajorTopicYN="N">case report</Keyword>
        <Keyword MajorTopicYN="N">interstitial lung disease</Keyword>
        <Keyword MajorTopicYN="N">myositis-associated antibody</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-787/coif). The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35434024</ArticleId>
        <ArticleId IdType="pmc">PMC9011269</ArticleId>
        <ArticleId IdType="doi">10.21037/atm-22-787</ArticleId>
        <ArticleId IdType="pii">atm-10-06-383</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Uribe L, Ronderos DM, Díaz MC, et al. 
Antisynthetase antibody syndrome: case report and review of the literature.
Clin Rheumatol
2013;32:715-9. 10.1007/s10067-013-2207-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-013-2207-5</ArticleId>
            <ArticleId IdType="pubmed">23423441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.
Rheumatol Int
2017;37:1323-33. 10.1007/s00296-017-3718-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-017-3718-1</ArticleId>
            <ArticleId IdType="pubmed">28417151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connors GR, Christopher-Stine L, Oddis CV, et al. 
Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?
Chest
2010;138:1464-74. 10.1378/chest.10-0180</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.10-0180</ArticleId>
            <ArticleId IdType="pubmed">21138882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Decker P, Moulinet T, Lopez B, et al. 
Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases.
European journal of internal medicine
2021;91:45-52. 10.1016/j.ejim.2021.04.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejim.2021.04.020</ArticleId>
            <ArticleId IdType="pubmed">33972152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie I, Hatron PY, Dominique S, et al. 
Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
Semin Arthritis Rheum
2012;41:890-9. 10.1016/j.semarthrit.2011.09.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2011.09.008</ArticleId>
            <ArticleId IdType="pubmed">22078416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi S, Yuxin S, Hui H, et al. Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease. Rheumatology (Oxford), 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34128956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauhammer J, Blank N, Max R, et al. 
Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
J Rheumatol
2016;43:1566-74. 10.3899/jrheum.150844</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.150844</ArticleId>
            <ArticleId IdType="pubmed">27252419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
Rheumatol Int
2016;36:935-43. 10.1007/s00296-016-3494-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-016-3494-3</ArticleId>
            <ArticleId IdType="pubmed">27193471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamora AC, Hoskote SS, Abascal-Bolado B, et al. 
Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome.
Respir Med
2016;118:39-45. 10.1016/j.rmed.2016.07.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2016.07.009</ArticleId>
            <ArticleId IdType="pubmed">27578469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courties A, Lidove O, Maisonobe T, et al. 
Antisynthetase syndrome and lung carcinoma: a fortuitous association?
Rev Med Interne
2014;35:271-3. 10.1016/j.revmed.2013.04.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.revmed.2013.04.012</ArticleId>
            <ArticleId IdType="pubmed">23726930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strandberg L, Ambrosi A, Espinosa A, et al. 
Interferon-α induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies.
J Clin Immunol
2008;28:220-31. 10.1007/s10875-007-9157-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-007-9157-0</ArticleId>
            <ArticleId IdType="pubmed">18071879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt J.
Current Classification and Management of Inflammatory Myopathies.
J Neuromuscul Dis
2018;5:109-29. 10.3233/JND-180308</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JND-180308</ArticleId>
            <ArticleId IdType="pmc">PMC6004913</ArticleId>
            <ArticleId IdType="pubmed">29865091</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
